aluates Reports

$ 0.0

Automative

Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Research Report 2025

Published Date: June 2025

Report Code: QYRE-Auto-8G12702

Global Postmenopausal Vaginal Atrophy PVA Treatment Industry Research Report Growth Trends and Competitive Analysis 2022 2028

BUY CHAPTERS

Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Research Report 2025

Code: QYRE-Auto-8G12702

Report

June 2025

Pages:88

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

EndoCeutics

Upsher-Smith Laboratories

TherapeuticsMD

Bionovo

Pfizer Inc

Novo Nordisk

Allergan plc

Shionogi

Ligand Pharmaceuticals

Bayer

Pantarhei Bioscience

Foamix Pharmaceuticals

Pep-Tonic Medical

Teva Pharmaceuticals

Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Postmenopausal Vaginal Atrophy (PVA) Treatment Market

The global market for Postmenopausal Vaginal Atrophy (PVA) Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Postmenopausal Vaginal Atrophy (PVA) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Postmenopausal Vaginal Atrophy (PVA) Treatment.

The Postmenopausal Vaginal Atrophy (PVA) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Postmenopausal Vaginal Atrophy (PVA) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Postmenopausal Vaginal Atrophy (PVA) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Postmenopausal Vaginal Atrophy (PVA) Treatment Market Report

Report Metric	Details
Report Name	Postmenopausal Vaginal Atrophy (PVA) Treatment Market
CAGR	5%
Segment by Type	Systemic Estrogen Treatments Non-estrogenic Therapies
Segment by Application	Hospital Clinics
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	EndoCeutics, Upsher-Smith Laboratories, TherapeuticsMD, Bionovo, Pfizer, Novo Nordisk, Allergan, Shionogi, Ligand Pharmaceuticals, Bayer, Pantarhei Bioscience, Foamix Pharmaceuticals, Pep-Tonic Medical, Teva Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Postmenopausal Vaginal Atrophy (PVA) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Postmenopausal Vaginal Atrophy (PVA) Treatment Market report?

Ans: The main players in the Postmenopausal Vaginal Atrophy (PVA) Treatment Market are EndoCeutics, Upsher-Smith Laboratories, TherapeuticsMD, Bionovo, Pfizer, Novo Nordisk, Allergan, Shionogi, Ligand Pharmaceuticals, Bayer, Pantarhei Bioscience, Foamix Pharmaceuticals, Pep-Tonic Medical, Teva Pharmaceuticals

What are the Application segmentation covered in the Postmenopausal Vaginal Atrophy (PVA) Treatment Market report?

Ans: The Applications covered in the Postmenopausal Vaginal Atrophy (PVA) Treatment Market report are Hospital, Clinics

What are the Type segmentation covered in the Postmenopausal Vaginal Atrophy (PVA) Treatment Market report?

Ans: The Types covered in the Postmenopausal Vaginal Atrophy (PVA) Treatment Market report are Systemic Estrogen Treatments, Non-estrogenic Therapies

Recommended Reports

Gynecological Disorders

Menopause and Hormonal Therapy

Pelvic and Urinary Treatments

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Systemic Estrogen Treatments

1.2.3 Non-estrogenic Therapies

1.3 Market by Application

1.3.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinics

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Perspective (2020-2031)

2.2 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Growth Trends by Region

2.2.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Postmenopausal Vaginal Atrophy (PVA) Treatment Historic Market Size by Region (2020-2025)

2.2.3 Postmenopausal Vaginal Atrophy (PVA) Treatment Forecasted Market Size by Region (2026-2031)

2.3 Postmenopausal Vaginal Atrophy (PVA) Treatment Market Dynamics

2.3.1 Postmenopausal Vaginal Atrophy (PVA) Treatment Industry Trends

2.3.2 Postmenopausal Vaginal Atrophy (PVA) Treatment Market Drivers

2.3.3 Postmenopausal Vaginal Atrophy (PVA) Treatment Market Challenges

2.3.4 Postmenopausal Vaginal Atrophy (PVA) Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Postmenopausal Vaginal Atrophy (PVA) Treatment Players by Revenue

3.1.1 Global Top Postmenopausal Vaginal Atrophy (PVA) Treatment Players by Revenue (2020-2025)

3.1.2 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue

3.4 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Concentration Ratio

3.4.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in 2024

3.5 Global Key Players of Postmenopausal Vaginal Atrophy (PVA) Treatment Head office and Area Served

3.6 Global Key Players of Postmenopausal Vaginal Atrophy (PVA) Treatment, Product and Application

3.7 Global Key Players of Postmenopausal Vaginal Atrophy (PVA) Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Postmenopausal Vaginal Atrophy (PVA) Treatment Breakdown Data by Type

4.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Historic Market Size by Type (2020-2025)

4.2 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Forecasted Market Size by Type (2026-2031)

5 Postmenopausal Vaginal Atrophy (PVA) Treatment Breakdown Data by Application

5.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Historic Market Size by Application (2020-2025)

5.2 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size (2020-2031)

6.2 North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2020-2025)

6.4 North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size (2020-2031)

7.2 Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2020-2025)

7.4 Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size (2020-2031)

8.2 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size (2020-2031)

9.2 Latin America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2020-2025)

9.4 Latin America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size (2020-2031)

10.2 Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 EndoCeutics

11.1.1 EndoCeutics Company Details

11.1.2 EndoCeutics Business Overview

11.1.3 EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.1.4 EndoCeutics Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.1.5 EndoCeutics Recent Development

11.2 Upsher-Smith Laboratories

11.2.1 Upsher-Smith Laboratories Company Details

11.2.2 Upsher-Smith Laboratories Business Overview

11.2.3 Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.2.4 Upsher-Smith Laboratories Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.2.5 Upsher-Smith Laboratories Recent Development

11.3 TherapeuticsMD

11.3.1 TherapeuticsMD Company Details

11.3.2 TherapeuticsMD Business Overview

11.3.3 TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.3.4 TherapeuticsMD Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.3.5 TherapeuticsMD Recent Development

11.4 Bionovo

11.4.1 Bionovo Company Details

11.4.2 Bionovo Business Overview

11.4.3 Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.4.4 Bionovo Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.4.5 Bionovo Recent Development

11.5 Pfizer

11.5.1 Pfizer Company Details

11.5.2 Pfizer Business Overview

11.5.3 Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.5.4 Pfizer Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.5.5 Pfizer Recent Development

11.6 Novo Nordisk

11.6.1 Novo Nordisk Company Details

11.6.2 Novo Nordisk Business Overview

11.6.3 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.6.4 Novo Nordisk Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.6.5 Novo Nordisk Recent Development

11.7 Allergan

11.7.1 Allergan Company Details

11.7.2 Allergan Business Overview

11.7.3 Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.7.4 Allergan Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.7.5 Allergan Recent Development

11.8 Shionogi

11.8.1 Shionogi Company Details

11.8.2 Shionogi Business Overview

11.8.3 Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.8.4 Shionogi Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.8.5 Shionogi Recent Development

11.9 Ligand Pharmaceuticals

11.9.1 Ligand Pharmaceuticals Company Details

11.9.2 Ligand Pharmaceuticals Business Overview

11.9.3 Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.9.4 Ligand Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.9.5 Ligand Pharmaceuticals Recent Development

11.10 Bayer

11.10.1 Bayer Company Details

11.10.2 Bayer Business Overview

11.10.3 Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.10.4 Bayer Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.10.5 Bayer Recent Development

11.11 Pantarhei Bioscience

11.11.1 Pantarhei Bioscience Company Details

11.11.2 Pantarhei Bioscience Business Overview

11.11.3 Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.11.4 Pantarhei Bioscience Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.11.5 Pantarhei Bioscience Recent Development

11.12 Foamix Pharmaceuticals

11.12.1 Foamix Pharmaceuticals Company Details

11.12.2 Foamix Pharmaceuticals Business Overview

11.12.3 Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.12.4 Foamix Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.12.5 Foamix Pharmaceuticals Recent Development

11.13 Pep-Tonic Medical

11.13.1 Pep-Tonic Medical Company Details

11.13.2 Pep-Tonic Medical Business Overview

11.13.3 Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.13.4 Pep-Tonic Medical Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.13.5 Pep-Tonic Medical Recent Development

11.14 Teva Pharmaceuticals

11.14.1 Teva Pharmaceuticals Company Details

11.14.2 Teva Pharmaceuticals Business Overview

11.14.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Introduction

11.14.4 Teva Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

11.14.5 Teva Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

EndoCeutics

Upsher-Smith Laboratories

TherapeuticsMD

Bionovo

Pfizer Inc

Novo Nordisk

Allergan plc

Shionogi

Ligand Pharmaceuticals

Bayer

Pantarhei Bioscience

Foamix Pharmaceuticals

Pep-Tonic Medical

Teva Pharmaceuticals

List of Tables

Table 1. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Systemic Estrogen Treatments

Table 3. Key Players of Non-estrogenic Therapies

Table 4. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Region (2020-2025)

Table 8. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Region (2026-2031)

Table 10. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Trends

Table 11. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Drivers

Table 12. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Challenges

Table 13. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Restraints

Table 14. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Players (2020-2025)

Table 16. Global Top Postmenopausal Vaginal Atrophy (PVA) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment as of 2024)

Table 17. Ranking of Global Top Postmenopausal Vaginal Atrophy (PVA) Treatment Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Postmenopausal Vaginal Atrophy (PVA) Treatment, Headquarters and Area Served

Table 20. Global Key Players of Postmenopausal Vaginal Atrophy (PVA) Treatment, Product and Application

Table 21. Global Key Players of Postmenopausal Vaginal Atrophy (PVA) Treatment, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Type (2020-2025)

Table 25. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Type (2026-2031)

Table 27. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Application (2020-2025)

Table 29. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Application (2026-2031)

Table 31. North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 46. EndoCeutics Company Details

Table 47. EndoCeutics Business Overview

Table 48. EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 49. EndoCeutics Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 50. EndoCeutics Recent Development

Table 51. Upsher-Smith Laboratories Company Details

Table 52. Upsher-Smith Laboratories Business Overview

Table 53. Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 54. Upsher-Smith Laboratories Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 55. Upsher-Smith Laboratories Recent Development

Table 56. TherapeuticsMD Company Details

Table 57. TherapeuticsMD Business Overview

Table 58. TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 59. TherapeuticsMD Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 60. TherapeuticsMD Recent Development

Table 61. Bionovo Company Details

Table 62. Bionovo Business Overview

Table 63. Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 64. Bionovo Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 65. Bionovo Recent Development

Table 66. Pfizer Company Details

Table 67. Pfizer Business Overview

Table 68. Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 69. Pfizer Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 70. Pfizer Recent Development

Table 71. Novo Nordisk Company Details

Table 72. Novo Nordisk Business Overview

Table 73. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 74. Novo Nordisk Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 75. Novo Nordisk Recent Development

Table 76. Allergan Company Details

Table 77. Allergan Business Overview

Table 78. Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 79. Allergan Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 80. Allergan Recent Development

Table 81. Shionogi Company Details

Table 82. Shionogi Business Overview

Table 83. Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 84. Shionogi Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 85. Shionogi Recent Development

Table 86. Ligand Pharmaceuticals Company Details

Table 87. Ligand Pharmaceuticals Business Overview

Table 88. Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 89. Ligand Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 90. Ligand Pharmaceuticals Recent Development

Table 91. Bayer Company Details

Table 92. Bayer Business Overview

Table 93. Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 94. Bayer Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 95. Bayer Recent Development

Table 96. Pantarhei Bioscience Company Details

Table 97. Pantarhei Bioscience Business Overview

Table 98. Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 99. Pantarhei Bioscience Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 100. Pantarhei Bioscience Recent Development

Table 101. Foamix Pharmaceuticals Company Details

Table 102. Foamix Pharmaceuticals Business Overview

Table 103. Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 104. Foamix Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 105. Foamix Pharmaceuticals Recent Development

Table 106. Pep-Tonic Medical Company Details

Table 107. Pep-Tonic Medical Business Overview

Table 108. Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 109. Pep-Tonic Medical Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 110. Pep-Tonic Medical Recent Development

Table 111. Teva Pharmaceuticals Company Details

Table 112. Teva Pharmaceuticals Business Overview

Table 113. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product

Table 114. Teva Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025) & (US$ Million)

Table 115. Teva Pharmaceuticals Recent Development

Table 116. Research Programs/Design for This Report

Table 117. Key Data Information from Secondary Sources

Table 118. Key Data Information from Primary Sources

Table 119. Authors List of This Report

List of Figures

Figure 1. Postmenopausal Vaginal Atrophy (PVA) Treatment Picture

Figure 2. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Type: 2024 VS 2031

Figure 4. Systemic Estrogen Treatments Features

Figure 5. Non-estrogenic Therapies Features

Figure 6. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Application: 2024 VS 2031

Figure 8. Hospital Case Studies

Figure 9. Clinics Case Studies

Figure 10. Postmenopausal Vaginal Atrophy (PVA) Treatment Report Years Considered

Figure 11. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 12. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Region: 2024 VS 2031

Figure 14. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Players in 2024

Figure 15. Global Top Postmenopausal Vaginal Atrophy (PVA) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy (PVA) Treatment as of 2024)

Figure 16. The Top 10 and 5 Players Market Share by Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue in 2024

Figure 17. North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 18. North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2020-2031)

Figure 19. United States Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2020-2031)

Figure 23. Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. France Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. U.K. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Region (2020-2031)

Figure 31. China Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. India Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Australia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Latin America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2020-2031)

Figure 39. Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2020-2031)

Figure 43. Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. EndoCeutics Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 47. Upsher-Smith Laboratories Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 48. TherapeuticsMD Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 49. Bionovo Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 50. Pfizer Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 51. Novo Nordisk Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 52. Allergan Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 53. Shionogi Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 54. Ligand Pharmaceuticals Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 55. Bayer Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 56. Pantarhei Bioscience Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 57. Foamix Pharmaceuticals Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 58. Pep-Tonic Medical Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 59. Teva Pharmaceuticals Revenue Growth Rate in Postmenopausal Vaginal Atrophy (PVA) Treatment Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Postmenopausal Vaginal Atrophy Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Postmenopausal Vaginal Atrophy Drugs Market Insights Forecast to 2030

Vulvar and Vaginal Atrophy Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Vaginal and Vulval Inflammatory Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Vasomotor Symptoms of Menopause Treatment Market Research Report 2024

Global Vaginitis Therapeutics Market Insights Forecast to 2030

Vaginal Antifungal Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Vulvodynia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Menopause Hormonal Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Female Urinary Incontinence Treatment Market Research Report 2024

Male Menopause Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Post Menopausal Osteoporosis Drug Market Research Report 2024

Drugs for Vaginal Fungal Infections Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Menopause Hormonal Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cervical Therapy Apparatus Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Incontinence Treatment System Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Urinary Incontinence Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Menopausal Hot Flashes Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Postural Therapy Beds Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions